Última actualización 18 de julio de 2026
Key finding
HbA1c decreased significantly from baseline in responders.
This study evaluated how baseline characteristics and metabolomic features can predict the effectiveness of exenatide in lowering glucose levels in patients with type 2 diabetes mellitus (T2DM).
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated how baseline characteristics and metabolomic features can predict the effectiveness of exenatide in lowering glucose levels in patients with type 2 diabetes mellitus (T2DM).
Understanding which patients are likely to benefit from exenatide can help clinicians tailor diabetes treatment more effectively. By identifying responders based on baseline characteristics and metabolomic profiles, healthcare providers can optimize management strategies for T2DM, potentially improving patient outcomes.
The study included only one intervention arm, limiting comparative analysis. Results may not be generalizable to all T2DM populations. Potential confounding factors were not fully addressed.
Published in
Publication details and source links for this paper.
Yunyi L, Jin Y, Qi W, et al. Combination of baseline characteristics and metabolomic features predicts glucose-lowering efficacy of exenatide in T2DM. Metabolism Open. 2026;29:100453. doi:10.1016/j.metop.2026.100453
HbA1c decreased by 1.54% (p=0.001) in responders.
Fasting plasma glucose decreased by 1.79 mmol/L (p=0.001) in responders.
Body weight decreased by 2.1 kg (p=0.001) in responders.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Exenatide and Alanine Aminotransferase (ALT), BMI, Body weight, and 7 more.
This study contributes evidence to
Primary intervention
Exenatide
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
10
Evidence pairs
791
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Exenatide → Alanine Aminotransferase (ALT)
Exenatide → Alanine Aminotransferase (ALT)
Exenatide → Change in Aspartate Aminotransferase Levels
Exenatide → Change in Aspartate Aminotransferase Levels
Exenatide → Fasting Plasma Glucose (FPG)
Exenatide → Fasting Plasma Glucose (FPG)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Adipokine and Angiogenic Markers, GLP-1 Receptor Agonists and Change in Aspartate Aminotransferase Levels.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Change in Aspartate Aminotransferase Levels
Measures Change in Aspartate Aminotransferase Levels as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with generally consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
